AzTrials
AzTrials

Cerebral Blood FlowNCT07212712

The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans

A study testing GnRH antagonist, Estradiol (E2) and Testosterone in people with Cerebral Blood Flow and Cerebral Blood Flow Regulation, run by University of British Columbia at 1 site in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Read more about this study

Who is it for?
Ages 18 to 40 weeksHealthy volunteers can take part
What is being tested?
GnRH antagonist, Estradiol (E2) and Testosterone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteCanada
Study dates
1 Apr 2026to 31 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 weeks
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • The investigators will recruit healthy young (18-40 years) males (n = 25) and females (n = 25). Females must be naturally cycling (i.e., no oral or hormonal contraceptives), not pregnant, and premenopausal. Participants must be normotensive (<140/90 mmHg \& >90/60 mmHg) and have no medical history of cerebrovascular, cardiopulmonary, cardiovascular, neuromuscular, and renal disease assessed by a study questionnaire. A recent physical examination (within 1 year of participation) from a family physician or a completed physical examination by the study doctor is required prior to participation. All subjects will sign an informed consent form prior to participation.
  • Participants will be excluded if they meet any of the following criteria:
  • Hypertensive (≥140/90 mmHg) or hypotensive (≤90/60 mmHg)
  • BMI ≥ 30 kg/m2
  • Fasting blood glucose ≥ 100 mg/dL
  • Abnormal results on standard blood hematology tests (e.g., complete blood count, comprehensive metabolic panel)
Show all 20Show fewer
  • Males with hypogonadism (total testosterone ≤ 262 ng/dL, per Endocrine Society recommendations)
  • Any history of cerebrovascular, cardiopulmonary, cardiovascular, neuromuscular, or renal disease
  • Any liver dysfunction or disease
  • Taking any cardiovascular medications or medications that would interfere with study medications (e.g., strong organic anion transporting polypeptide 1B1 inhibitors)
  • Contraindications or sensitivities to study medications
  • Current eating disorder (defined as >2 on the 'SCOFF' questionnaire 67)
  • Current smokers
  • Females with an irregular menstrual cycle or any medical conditions affecting the menstrual cycle (normal cycle defined as 21-35 days from menstrual cycle diary)
  • Females who are pregnant (assessed with pregnancy test at screening and prior to starting medications), breastfeeding, or planning to conceive within 3 months
  • Females using hormonal birth control (Copper intrauterine devices [IUDs] will be allowed as they do not change systemic hormone levels)
  • Females who are peri- or postmenopausal (as determined by STRAW criteria 68)
  • History of hormone-sensitive cancers (i.e., breast, ovarian, uterine or prostate)
  • Z-score < -2 as assessed with DXA scan (to determine risk of decrease in bone mineral density)
  • Assessed using the Center for Epidemiologic Studies Depression (CES-D) scale, participants with a score > 16 at screening unless otherwise approved by the study MD

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Lauren Maier, MSc contact

250 878 6171

laurenm7@student.ubc.ca

Canada1 site
  • University of British Columbia - Okanagan

    Kelowna, British Columbia, V1V 1V7

    Lauren Maier, MSc, 250 878 6171, laurenm7@student.ubc.ca

    Philip Ainslie, PhD

Other trials in Canada

About this study

Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.

Read the detailed description

Sex hormones have been demonstrated to influence cardiovascular function in humans and cerebrovascular function in preclinical models. Declines in gonadal function have been attributed to the development of chronic disease risk in humans, including stroke, cognitive decline and dementia but the pathophysiology of these disorders remains unclear, in part, because there remains a gap-in-knowledge of the regulatory actions of sex hormones on cerebrovascular function in males and females. Therefore, the major goal of this application is to determine the independent regulatory actions of testosterone and estradiol on cerebrovascular function in males and females, respectively. Determination of this fundamental physiology is needed to inform future studies evaluating the sex-specific pathology physiology of chronic diseases and/or the development of efficacious sex-specific interventions for improving chronic disease risk.

To the investigator's knowledge, there is minimal evidence in humans isolating the influence of these hormones on basic mechanisms of brain blood flow regulation in vivo. Cross-sectional studies demonstrate younger females show significantly higher resting cerebral blood flow (CBF) compared to young males however, this sex difference in CBF is lost after midlife. This loss of female 'protection' on CBF is often attributed to hormonal differences following menopause. Further evidence in animal models support a key role of estrogen in both resting CBF and reactivity. Crucially, these findings have not been replicated in humans, due to natural fluctuations in sex hormones. Research investigating natural hormonal fluctuations throughout the menstrual cycle and menopause provides conflicting findings, falling short on isolating the specific hormonal influences on cerebrovascular physiology likely due large interindividual variations in hormone levels and cycle lengths.

Similarly, the presence of normal physiological levels of testosterone has been shown to influence chronic disease risk including cardiovascular disease risk and peripheral vascular function. However, whether testosterone concentrations influence CBF in males remains incompletely understood with one study showing testosterone may enhance CBF in older hypogonadal men. Furthermore, testosterone can be converted to estradiol via a specific enzyme, aromatase; thus, it is unclear whether the findings of prior study were related to changes in testosterone or estradiol concentrations in hypogonadal males. A definitive role of these hormones in brain blood flow regulation remains to be elucidated.

Current published studies suffer from several key limitations. First, many studies are unable to isolate the impact of hormones and their causality on cerebrovascular function in humans. The inability to replicate findings from direct hormone manipulation in animals with observational data during natural hormone cycling in humans suggests measuring females during their menstrual cycles is not adequate for understanding the direct role of these hormones. There is a very large degree of variation both between and within individuals throughout their menstrual cycles, proving difficult to relate changes in function with hormone levels. In males, very limited research exists investigating how testosterone influences cerebrovascular function. Further, this research will have direct implications for peri- and postmenopausal women, who are regularly prescribed exogenous estradiol for symptom management. Understanding the role of hormones in healthy physiology will allow direct translation to a myriad of hormonal disorders, including endometriosis, polycystic ovary syndrome, uterine fibroids, and hypogonadism. Individuals with endometriosis are commonly prescribed oral GnRH antagonist, which can be combined with estradiol for prolonged use (> 6 months). Similarly, males with hypogonadism often supplement testosterone for prolonged periods with minimal negative effects.

This study will allow for isolation of estradiol in females and testosterone in males to investigate their role on cerebrovascular regulation. In contrast with previous observational studies throughout the menstrual cycle and menopause in females and aging in males, this study will provide a controlled environment to determine causal relationships between hormones and physiology without the presence of confounding variables. This study will address the gap in literature between interventional models in animals and observational studies in healthy humans. This study will provide fundamental understandings of healthy physiology that will shape future studies to investigate the role of estradiol and testosterone in clinical populations.

The primary objective of this study is to determine how estrogen and testosterone influence cerebral blood flow and metabolism.

Primary Hypotheses:

  • Cerebral blood flow and cerebral metabolic rate of oxygen consumption will be reduced in females with hormone blockade but augmented with estrogen add-back.
  • Cerebral blood flow and cerebral metabolic rate of oxygen consumption will be increased in males with hormone blockade but attenuated with testosterone add-back.

To meet cerebral metabolic demands, the brain is dependent upon constant oxygen and nutrient delivery. Cerebral oxygen delivery is directly proportional to CBF and the arterial oxygen content (CaO2); it is widely known that CaO2 is lower in females, owing to the impact of anemia, hormones, and other related factors (e.g., hemoglobin, menses). To compensate, in order to maintain a stable cerebral oxygen delivery, females increase their resting CBF. Indeed, both CaO2 and hemoglobin levels are related to CBF levels. Very limited research has investigated whether cerebral metabolism differs between young males and females, with one study reporting a similar cerebral metabolic rate of oxygen (CMRO2), and another reporting higher CMRO2 in females. As cerebral metabolism is determined by CBF and the degree of oxygen extracted by the brain (oxygen extraction fraction; OEF), we must measure CMRO2 to appropriately interpret differences in CBF throughout our intervention.

Measuring CMRO₂ with the direct, invasive Fick method is the gold standard approach. By directly quantifying CBF and the arterial-venous difference in oxygen content, the Fick approach provides an absolute and internally consistent measure of brain oxygen consumption, rather than an indirect surrogate (as used with MRI, for example). This directness minimizes reliance on modeling assumptions and calibration factors that can introduce systematic bias in non-invasive techniques. As a result, Fick-based CMRO₂ measurements offer high accuracy and reproducibility; this approach is often used for validating newer imaging methods and for studies in which precise quantification of cerebral metabolism is essential. In terms of CBF, the majority of studies that of explored sex differences have typically incorporated measures of intracranial velocity via transcranial Doppler (TCD) rather than assessment flow. In this study, we will employ contemporary measures of Duplex ultrasound which measures extracranial flow and further validates our inclusion of CMRO2 measures.

Despite its invasiveness, the Fick method offers unique benefits that justify its use in select experimental and clinical contexts. Because it yields absolute metabolic values, the direct Fick method facilitates meaningful comparisons across subjects, conditions, and studies for the critical benchmark and gold-standard for understanding cerebral energetics. Compared with MRI-based approaches, the Fick technique quantifies CMRO2 from measured cerebral blood flow and the arterial-venous oxygen content difference, yielding an absolute metabolic rate with minimal dependence on modeling assumptions. In contrast, MRI-derived CMRO2 estimates typically rely on indirect contrasts (e.g., BOLD, ASL) and biophysical models that require assumptions about vascular geometry, baseline physiology (eg., hemoglobin levels), and coupling between flow, volume, and metabolism, all of which can vary across subjects and conditions. As a result, the invasive Fick method offers superior accuracy and interpretability, particularly when precise quantification is required or when validating MRI-based metabolic measurements. While PET imaging would be considered the gold standard to measure regional blood flow and oxygen or glucose metabolism by tracking the uptake of injected radioactive tracers (usually H₂¹⁵O), it is also invasive, requiring injected radioactive tracers and does not provide information on global CMRO2 or lactate metabolism. For a more extensive review of the limitations of PET imaging for global cerebral metabolism, please see Duffy et al. Therefore, neither PET nor MRI imaging can be easily used when common stressors are implemented (e.g., exercise, changes in partial pressures of oxygen and carbon dioxide) to provide an index of brain resilience.

Being tested
GnRH antagonist, Estradiol (E2), Testosterone, Anastrozole (Arimidex)
Medical subject headings
Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GnRH antagonistDrug

    blockade of hormone production

  • Estradiol (E2)Drug

    Estrogen add-back in females

  • TestosteroneDrug

    testosterone add-back in males

  • Anastrozole (Arimidex)Drug

    Prevention of testosterone conversion to estrogen in males

Study groups in NCT07212712
Study groupRoleWhat they receive
Hormone ManipulationExperimentalParticipants will act as their own controls, completing the experiment 3 times. First, with no hormone manipulation; second, with blockade of hormone production; third, with hormone add-back.
Receives: Drug: GnRH antagonist; Drug: Estradiol (E2); Drug: Testosterone; Drug: Anastrozole (Arimidex)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cerebral blood flow responses to estrogen and testosterone

    To determine how cerebral blood flow regulation is altered by estrogen and testosterone concentrations. Measured through doppler ultrasonography, and reported in mL/min.

    Measured: 7 days

  2. Cerebral metabolic changes with estrogen and testosterone

    Measured as cerebral metabolic rate of oxygen consumption. Determined using arterial and internal jugular vein blood sampling coupled with doppler ultrasound, to determine metabolism directly using the Fick method.

    Measured: 4 days

Secondary outcomes (2)
  1. Hormone influences on appetite sensations

    How estrogen and testosterone influence appetite sensations (visual analog scale)

    Measured: 7 days

  2. How estrogen and testosterone influence energy intake

    dietary intake, measured with self-report questionnaire

    Measured: 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Oct 2025
  2. Study start1 Apr 2026 (estimated)
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07212712
Sponsor's protocol ID
H25-00385
Status last verified
Feb 2026
First submitted
24 Sep 2025
Last updated
10 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: We will share individual data from published results on request.

Publications

  • Muer JD, Didier KD, Wannebo BM, Sanchez S, Khademi Motlagh H, Haley TL, Carter KJ, Banks NF, Eldridge MW, Serlin RC, Wieben O, Schrage WG. Sex differences in gray matter, white matter, and regional brain perfusion in young, healthy adults. Am J Physiol Heart Circ Physiol. 2024 Oct 1;327(4):H847-H858. doi: 10.1152/ajpheart.00341.2024. Epub 2024 Aug 9.

    PubMed 39120466
  • Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, Khatiwoda A, Lisabeth L. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008 Oct;7(10):915-26. doi: 10.1016/S1474-4422(08)70193-5. Epub 2008 Aug 21.

    PubMed 18722812
  • Moreau KL, Hildreth KL, Klawitter J, Blatchford P, Kohrt WM. Decline in endothelial function across the menopause transition in healthy women is related to decreased estradiol and increased oxidative stress. Geroscience. 2020 Dec;42(6):1699-1714. doi: 10.1007/s11357-020-00236-7. Epub 2020 Aug 8.

    PubMed 32770384

Questions about this trial

What is this clinical trial studying?

A study testing GnRH antagonist, Estradiol (E2) and Testosterone in people with Cerebral Blood Flow and Cerebral Blood Flow Regulation, run by University of British Columbia at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 10 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lauren Maier, MSc (250 878 6171, laurenm7@student.ubc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cerebral blood flow responses to estrogen and testosterone (time frame: 7 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07212712, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in